# EDGAR Filing Document

**Accession Number:** 0001850051
**File Stem:** 0001104659-23-017381
**Filing Date:** 2023-2
**Character Count:** 11927
**Document Hash:** a72eeb2c4d75d3baff9dd5a8e2d4fe22
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-23-017381.hdr.sgml**: 20230209

**ACCESSION NUMBER**: 0001104659-23-017381

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20230208

**ITEM INFORMATION**: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230209

**DATE AS OF CHANGE**: 20230209

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Intelligent Medicine Acquisition Corp.
- **CENTRAL INDEX KEY:** 0001850051
- **STANDARD INDUSTRIAL CLASSIFICATION:** BLANK CHECKS [6770]
- **IRS NUMBER:** 862283527
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41024
- **FILM NUMBER:** 23604757

**BUSINESS ADDRESS:**
- **STREET 1:** 9001 BURDETTE RD.
- **CITY:** BETHESDA
- **STATE:** MD
- **ZIP:** 20817
- **BUSINESS PHONE:** 202-905-5834

**MAIL ADDRESS:**
- **STREET 1:** 9001 BURDETTE RD.
- **CITY:** BETHESDA
- **STATE:** MD
- **ZIP:** 20817

?xml version="1.0" encoding="utf-8"?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or Section 15(d)**

**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): February 8, 2023**

**INTELLIGENT MEDICINE ACQUISITION CORP.**

**(Exact name of registrant as specified in its charter)**

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-41024** | **86-2283527** |
| **(State or other jurisdiction of<br> incorporation or organization)** | **(Commission<br> File Number)** | **(I.R.S. Employer<br> Identification Number)** |

---

---

| | |
|:---|:---|
| **9001 Burdette Rd.**<br>**Bethesda, MD** | **20817** |
| **(Address of principal executive offices)** | **(Zip Code)** |

---

**(202) 905-5834**

**(Registrant's telephone number, including area code)**

**Not Applicable**

**(Former name, former address and former fiscal year, if changed since last report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

◻ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

◻ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

◻ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

◻ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading<br> Symbol(s)** | **Name of each exchange on<br> which registered** |
| Units, each consisting of one share of Class A common stock and one-half of one redeemable warrant | IQMDU | The Nasdaq Stock Market LLC |
| Class A common stock, par value $0.0001 per share | IQMD | The Nasdaq Stock Market LLC |
| Warrants, each whole warrant exercisable for one share of Class A common stock at an exercise price of $11.50 per share | IQMDW | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company ⌧

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

**Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.**

On February 8, 2023, Intelligent Medicine Acquisition Corp. (the "Company") filed an amendment to its Amended and Restated Certificate of Incorporation (the "Amendment") with the State of Delaware., The Amendment is attached as Exhibit 3.1 hereto and the full text of such exhibit is incorporated by reference herein.

**Item 5.07. Submission of Matters to a Vote of Security Holders.**

On February 8, 2023, the Company held a special meeting of shareholders (the "Meeting") to approve the Extension Amendment Proposal, the Trust Amendment Proposal (collectively, the "Extension Proposals") and the Adjournment Proposal, each as more fully described in its definitive proxy statement, filed with United States Securities and Exchange Commission (the "Commission") on January 19, 2023..

The final voting results for the Extension Proposals were as follows:

<u>Proposal No. 1: The Extension Amendment Proposal: T</u>o amend the Company's amended and restated certificate of incorporation by allowing the Company to extend the date by which it has to consummate a business combination for an additional seven (7) months, from February 9, 2023 to September 9, 2023, or such earlier date as determined by the Company's board of directors, conditioned on the deposit of 200,000 shares of Class B common stock into the Company's IPO Trust Account. 

---

| | | |
|:---|:---|:---|
| **FOR** | **AGAINST** | **ABSTAIN** |
| 17071690 | 4600300 | 3936 |

---

<u>Proposal No. 2 The Trust Amendment Proposal:</u> To amend the Investment Management Trust Agreement, dated November 4, 2021, by and between the Company and Continental Stock Transfer & Company to authorize the Extension and its implementation by the Company.

---

| | | |
|:---|:---|:---|
| **FOR** | **AGAINST** | **ABSTAIN** |
| 17071841 | 4600149 | 3936 |

---

<u>Proposal No. 3: The Adjournment Proposal.</u> The Company had solicited proxies in favor of an Adjournment Proposal which would have given the Company authority to adjourn the Meeting to solicit additional proxies. As sufficient shares were voted in favor of the Extension Proposals, this proposal was not voted upon at the Meeting.

In connection with the vote to approve the Extension Proposals, the holders of 20,009,861 public shares of common stock of the Company properly exercised their right to redeem their shares (and did not withdraw their redemption) for cash at a redemption price of approximately $10.34 per share, for an aggregate redemption amount of approximately $206.9 million.

---

| | |
|:---|:---|
| **Item 8.01** | **Other Events.** |

---

&nbsp;&nbsp;&nbsp;&nbsp;On February 8, 2023, the Company's Sponsor, Intelligent Medicine Sponsor LLC, contributed to the Company for purposes of making a deposit into the Company's IPO Trust Account of an aggregate of 200,000 shares of Class B common stock for the benefit of the public shares that were not redeemed by the public shareholders in connection with the Meeting. Following the foregoing contribution, the Sponsor will own 4,700,000 shares of Class B common stock, which upon conversion of such shares into shares of Class A common stock would represent 80.1% of the outstanding shares.

The Sponsor also owns Private Placement Warrants exercisable for 9,245,000 shares of Class A common stock which are not currently exercisable.

---

| | |
|:---|:---|
| **Item 9.01** | **Financial Statements and Exhibits.** |

---

(d) Exhibits:

---

| | |
|:---|:---|
| **Exhibit** | **Description** |
| [3.1](tm236108d1_ex3-1.htm) | [Amendment to Amended and Restated Certificate of Incorporation](tm236108d1_ex3-1.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: February 9, 2023

---

| | |
|:---|:---|
| **INTELLIGENT MEDICINE ACQUISITION CORP.** | **INTELLIGENT MEDICINE ACQUISITION CORP.** |
| By: | /s/ Gregory C. Simon |
| Name: | Gregory C. Simon |
| Title: | Chief Executive Officer |

---

## Exhibit 3.1

**Exhibit 3.1**

**AMENDMENT**

**TO THE**

**AMENDED AND RESTATED** 

**CERTIFICATE OF INCORPORATION** 

**OF**

**INTELLIGENT MEDICINE ACQUISITION CORP.**

**Pursuant to Section 242 of the** 

**Delaware General Corporation Law**

**INTELLIGENT MEDICINE ACQUISITION CORP.** (the "Corporation"), a corporation organized and existing under the laws of the State of Delaware, does hereby certify as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. The name of the Corporation is Intelligent Medicine Acquisition Corp. The Corporation's Certificate of Incorporation was filed
in the office of the Secretary of State of the State of Delaware on February 25, 2021 (the "Original Certificate"). An Amended
and Restated Certificate of Incorporation was filed in the office of the Secretary of State of the State of Delaware on November 9, 2021
(the "Amended and Restated Certificate of Incorporation").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. This Amendment to the Amended and Restated Certificate of Incorporation amends the Amended and Restated Certificate of Incorporation
of the Corporation.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. This Amendment to the Amended and Restated Certificate of Incorporation was duly adopted by the affirmative vote of the holders of
65% of the stock entitled to vote at a meeting of stockholders in accordance with the provisions of Section 242 of the General Corporation
Law of the State of Delaware (the "DGCL").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. The text of Section 9.2(d) of Article IX is hereby amended and restated to read in full as follows:

(d) In the event that the Corporation has not consummated an initial Business Combination within 15 months from the closing of the Offering, the Board may extend the period of time to consummate an initial Business Combination (an "**Extension**") by an additional 7 months, or such earlier date as determined by the Board, for a total of up to 22 months to consummate an initial Business Combination, and if it fails to do so, the Corporation shall (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than ten business days thereafter subject to lawfully available funds therefor, redeem 100% of the Offering Shares in consideration of a per-share price, payable in cash, equal to the quotient obtained by dividing (A) the aggregate amount then on deposit in the Trust Account, including interest not previously released to the Corporation to pay its franchise and income taxes (less up to $100,000 of such net interest to pay dissolution expenses), by (B) the total number of then outstanding Offering Shares, which redemption will completely extinguish rights of the Public Stockholders (including the right to receive further liquidating distributions, if any), subject to applicable law, and

(iii) as promptly as reasonably possible following such redemption, subject to the approval of the remaining stockholders and the Board in accordance with applicable law, dissolve and liquidate, subject in each case to the Corporation's obligations under the DGCL to provide for claims of creditors and other requirements of applicable law.

**IN WITNESS WHEREOF**, Intelligent Medicine Acquisition Corp. has caused this Amendment to the Amended and Restated Certificate to be duly executed in its name and on its behalf by an authorized officer as of this day of February 8, 2023.

---

| | |
|:---|:---|
| **INTELLIGENT MEDICINE ACQUISITION CORP.** | **INTELLIGENT MEDICINE ACQUISITION CORP.** |
| By: | /s/ Gregory C. Simon |
| Name: | Gregory C. Simon |
| Title: | Chief Executive Officer |

---